Clinical Ink: 16th concurrent Alzheimer’s study
Clinical trial technology firm Clinical Ink has added its 16th concurrent Phase II/III Alzheimer’s disease study. The company supports sponsors working on such research by providing tools that allow for flexible data collection options for site-based and decentralized trials, supporting at-home collection of information, delivering data to trial teams in near-real time, and more.
Clinical Ink CEO Ed Seguine said, “Alzheimer’s is an especially complicated and challenging therapeutic area in which to conduct a clinical trial. Clinical Ink’s Lunexis eSource platform is custom-tailored for exactly such indications, enabling virtual and hybrid models driven by direct data capture. We’ve been pleased to work on therapies and devices offering such promise.”
